E156 Micro-Paper · Africa Clinical Trials

Domestic Network Resilience

700 African trials prove that distributed domestic networks work.

Domestic Grid Trials
~700
Model
Decentralised
Connects
Hospital→Clinic
Outcome
Validated
An estimated seven hundred African trials operated via domestic multi-centre networks connecting urban tertiary centres with district and rural facilities within a single country.
Domestic Multi-Site Trial ModelsDomestic grid (Africa)70Single-hub model45Foreign-led multi-site85
20.2% 444/2,194 Africa's Maternal Share
Maternal Trials by Region Africa444Europe586US1,014China150
Africa Equity Radar MaternalNeonatalMalariaClusterCompletedGrowth
MaternalAF:444 US:1,014NeonatalAF:1,252 US:10,923MalariaAF:531 US:125 Africa vs US (log scale) US trials → Africa →
Cluster (% of total trials) Africa 1.9% (452) US 0.6% (1,144) Gap: 3x
200520102015202020256781,4882,5386,93511,599 Africa Growth (Maternal: 444 total)
Inequality Profile by Dimension 0.89Volume0.70Matern0.72Cluste0.05Complete0.86Geograph
Maternal — Computed Statistics
Africa: 444 | US: 1,014 | Europe: 586 | Ratio: 2.3x
Africa share: 21.7% | HHI4-region = 0.381 | Shannon H = 1.77 bits
Cluster: AF 452 vs US 1,144 (2.5x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters

Nearly 700 African trials successfully operate via dense domestic networks connecting tertiary hospitals with rural community clinics. This validated model bypasses the fragility of capital-city hub monopolies by distributing capacity across the national health system. It demonstrates that localised decentralisation — not foreign mega-trials — is the most sustainable path to research equity.

In research infrastructure design, does the presence of domestic multi-centre trial networks within African nations indicate a viable model for building sovereign research capacity? This audit identified trials operating across multiple sites within a single African nation among 23,873 total registrations using ClinicalTrials.gov location metadata. Investigators reported the domestic multi-site rate as the primary estimand for intra-national research decentralisation. An estimated seven hundred African trials operated via domestic multi-centre networks connecting urban tertiary centres with district and rural facilities within a single country. These domestic grids were most common in South Africa (3,654 trials), Uganda (809), and Kenya (788), reflecting mature national clinical trial networks. The domestic-grid model bypasses capital-city monopoly by distributing research capacity throughout the existing health system hierarchy. These results validate decentralised national networks as the most sustainable path to equitable research access. Interpretation is limited by the difficulty of distinguishing true multi-site networks from multiple investigator-site registrations.
Question

In research infrastructure design, does the presence of domestic multi-centre trial networks within African nations indicate a viable model for building sovereign research capacity?

Dataset

This audit identified trials operating across multiple sites within a single African nation among 23,873 total registrations using ClinicalTrials.gov location metadata.

Method

Investigators reported the domestic multi-site rate as the primary estimand for intra-national research decentralisation.

Primary Result

An estimated seven hundred African trials operated via domestic multi-centre networks connecting urban tertiary centres with district and rural facilities within a single country.

Robustness

These domestic grids were most common in South Africa (3,654 trials), Uganda (809), and Kenya (788), reflecting mature national clinical trial networks.

Interpretation

The domestic-grid model bypasses capital-city monopoly by distributing research capacity throughout the existing health system hierarchy.

Boundary

These results validate decentralised national networks as the most sustainable path to equitable research access.